Diffuse Large B Cell Lymphoma - R-CHOP - BCL2 positive + LGALS3 expression

Association details:

Biomarker:	BCL2 positive + LGALS3 expression
Cancer:	Diffuse Large B Cell Lymphoma
Regimen:	R-CHOP (cyclophosphamide + doxorubicin hydrochloride + + Rituxan (rituximab) + vincristine)
Direction:	Resistant

Evidence:

Evidence Level:

Resistant: C3 – Early Trials

Source:

EHA 2022

Title:

BIOLOGICAL AND CLINICAL CORRELATES OF GALECTIN-3 (GAL-3) EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

Published date:

05/12/2022

Excerpt:

We analyzed clinical characteristics (age, sex, IPI factors, response to treatment, event-free survival (EFS) and overall survival (OS))...in newly diagnosed DLBCL patients treated with R-CHOP or similar regimens….BCL2 + patients fared significantly worse if they co-expressed gal-3 (EFS at 2 y 44% vs 73% (p=0,002) OS at 2 y 50% vs 74% (p=0,006))....Our results are in accordance with experimental data indicating that NF-κB stimulates gal-3 expression and that gal-3 potentiates the antiapoptotic effect of BCL2. Gal-3 is more frequently expressed in advanced-stage DLBCLs and those of non-GC subtype, consistent with its putative proliferative/antiapoptotic effect...